



## Request for Prior Authorization: Isotretinoin (Oral)

### CONTAINS CONFIDENTIAL PATIENT INFORMATION

Complete form in its entirety and fax to the Prior Authorization of Benefits Center at **844-512-9004**. If you have questions or need assistance, call the Provider Help Desk at **800-454-3730**.

1. Patient information	2. Physician information
Patient name: _____ Patient ID #: _____ Patient DOB: _____ Date of Rx: _____ Patient phone #: _____ Patient email address: _____	Prescribing physician: _____ Physician address: _____ Physician phone #: _____ Physician fax #: _____ Physician specialty: _____ Physician DEA: _____ Physician NPI #: _____ Physician email address: _____

3. Medication	4. Strength	5. Directions	6. Quantity per 30 days
_____	_____	_____	Specify: _____

**7. Diagnosis:** \_\_\_\_\_

**8. Approval criteria:** (Check all boxes that apply. Note: Any areas not filled out are considered not applicable to your patient and may affect the outcome of this request.)

Prior authorization (PA) is required for oral isotretinoin therapy. Payment will be considered for preferred oral isotretinoin products for moderate to severe acne under the following conditions: 1. There are documented trials and therapy failures of systemic antibiotic therapy and topical vitamin A derivative (tretinoin or adapalene) therapy. Documented trials and therapy failures of systemic antibiotic therapy and topical vitamin A derivative therapy are not required for approval for treatment of acne conglobata; and 2. Prescriber attests patient has enrolled in and meets all requirements of the iPLEDGE program. Payment for non-preferred oral isotretinoin products will be authorized only for cases in which there is documentation of trial(s) and therapy failure with a preferred agent(s). Initial authorization will be granted for up to 24 weeks. A minimum of eight weeks without therapy is required to consider subsequent authorizations.

The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

<p><b><u>Preferred</u></b></p> <p><input type="checkbox"/> Amnesteem   <input type="checkbox"/> Claravis   <input type="checkbox"/> Myorisan   <input type="checkbox"/> Zenatane</p>	<p><b><u>Non-Preferred</u></b></p> <p><input type="checkbox"/> Absorica</p>
--	---

Date of initial treatment: \_\_\_\_\_

\*If PA extension, please specify exact date range of last drug-free interval: From: \_\_\_\_\_ To: \_\_\_\_\_

**Documentation of trial failures with systemic antibiotic & vitamin A derivative:**

**Systemic antibiotic drug trial:** Drug name & dose: \_\_\_\_\_ Trial dates: \_\_\_\_\_

Failure reason: \_\_\_\_\_

**Vitamin A derivative drug trial:** Drug name & dose: \_\_\_\_\_ Trial dates: \_\_\_\_\_

Failure reason: \_\_\_\_\_

**Is patient enrolled in iPLEDGE program and meets all program requirements?**     No     Yes

Reason for use of non-preferred drug requiring prior approval: \_\_\_\_\_

Other medical conditions to consider: \_\_\_\_\_

Possible drug interactions/conflicting drug therapies: \_\_\_\_\_

***Attach lab results and other documentation as necessary.***

**9. Physician signature**

\_\_\_\_\_  
Prescriber or authorized signature

\_\_\_\_\_  
Date

**\*MUST MATCH PRESCRIBER LISTED ABOVE**

***IMPORTANT NOTE: In evaluating requests for prior authorization, the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.***